Cover Image
Market Research Report - 244305

Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022

Published by GlobalData
Published Content info 37 Pages
Price
Back to Top
Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022
Published: May 31, 2012 Content info: 37 Pages
Description

Summary

GlobalData's pharmaceuticals report, "Multaq (Atrial Fibrillation) - Analysis and Forecasts to 2022" provides Multaq global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US and EU5 (six major markets)
  • Analysis and review of Multaq including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Multaq including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2009-2022 for Multaq

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

Multaq, dronedarone, class III antiarrhythmic, paroxysmal atrial fibrillation, persistent atrial fibrillation, cardiovascular hospitalizations

Table of Contents

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Atrial Fibrillation Market
  • 2.2. Epidemiology
  • 2.3. Etiology and Risk Factors
    • 2.3.1. Symptoms associated with AF
  • 2.4. GlobalData Analysis and Forecasts Report Guidance

3. Atrial Fibrillation: Market Characterization

  • 3.1. Atrial Fibrillation Market
  • 3.2. Atrial Fibrillation Market Forecasts and CAGR
  • 3.3. Drivers of Atrial Fibrillation Market
    • 3.3.1. High Unmet need
    • 3.3.2. Strong Pipeline
    • 3.3.3. Increase in prevalence and ageing populations
    • 3.3.4. Organisation of Awareness Campaigns
  • 3.4. Barriers in Atrial Fibrillation Market
    • 3.4.1. Limitations in established therapies
    • 3.4.2. High cost of emerging therapies

4. Classification in Atrial Fibrillation: Introduction

  • 4.1. AF Classification
    • 4.1.1. Pathophysiology of AF
    • 4.1.2. Diagnosis in Atrial Fibrillation
    • 4.1.3. Impact of Atrial Fibrillation

5. Treatment Options and Management in Atrial Fibrillation

  • 5.1. Rate control and Rhythm control
  • 5.2. Rate Control Versus Rhythm Control

6. Multaq

  • 6.1. Introduction
  • 6.2. Mechanism of Action
  • 6.3. Clinical Studies
  • 6.4. Approval Status of Multaq
  • 6.5. Factors Affecting Sales of Eliquis
    • 6.5.1. Unique Drug with significant opportunity
    • 6.5.2. Low adverse effect profile
    • 6.5.3. Causative factor for Liver injury in some patients
    • 6.5.4. Second black box Warning for Multaq
  • 6.6. Drug Evaluation
    • 6.6.1. Drug Risk Benefit Score
    • 6.6.2. Intensity of Competition
  • 6.7. Sales Forecasts
    • 6.7.1. Target Patient Pool of Multaq
    • 6.7.2. Dosing
    • 6.7.3. Market Penetration
    • 6.7.4. Annual Cost of Therapy
    • 6.7.5. Global Sales Projections of Multaq

7. Appendix

  • 7.1. Market Definitions
  • 7.2. Abbreviations
  • 7.3. Research Methodology
    • 7.3.1. Coverage
    • 7.3.2. Secondary Research
    • 7.3.3. Forecasting
    • 7.3.4. Number of Patients Approved to Take the Drug
    • 7.3.5. Net Penetration of Drug
    • 7.3.6. Net Annual Dosing
    • 7.3.7. Annual Cost of Therapy
  • 7.4. Drug Sales Estimates Model
  • 7.5. Contact Us
  • 7.6. Disclaimer
  • 7.7. Sources

List of Tables

  • Table 1: Epidemiology of Atrial Fibrillation (2011)
  • Table 2: Increase in the Risk of AF in The Presence of Risk Factors
  • Table 3: Stratification of All Risk Factors For Atrial Fibrillation
  • Table 4: Atrial Fibrillation Classification
  • Table 5: Treatment Guidelines For the Management of Atrial Fibrillation
  • Table 6: Multaq, Approval Status, 2011
  • Table 7: Drug Risk Benefit Score of Multaq
  • Table 8: Multaq, Atrial Fibrilation, Global, Annual Cost of Therapy, 2011
  • Table 9: Multaq, Atrial Fibrillation, Global, Sales Forecasts ($m), 2009-2022
  • Table 10: Multaq, Atrial Fibrillation, The US, Sales Forecasts ($m), 2009-2022
  • Table 11: Multaq, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2010-2022
  • Table 12: Multaq, Atrial Fibrillation, France, Sales Forecasts ($m), 2010-2022
  • Table 13: Multaq, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2010-2022
  • Table 14: Multaq, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2010-2022
  • Table 15: Multaq, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2010-2022

List of Figures

  • Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011-2022
  • Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation
  • Figure 3: Increase of Prevalance Population in Atrial Fibrillation
  • Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation
  • Figure 5: Broad classification of Patterns in Atrial Fibrillation
  • Figure 6: Disease States Associated with Atrial Fibrillation, By (%)
  • Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF)
  • Figure 8: Management of Newly Discovered Atrial Fibrillation (AF)
  • Figure 9: Drug Model Diagram of Multaq
  • Figure 10: Multaq, Atrial Fibrillation, Global, Sales Forecasts ($m), 2009-2022
  • Figure 11: Multaq, Atrial Fibrillation, The US, Sales Forecasts ($m), 2009-2022
  • Figure 12: Multaq, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2010-2022
  • Figure 13: Multaq, Atrial Fibrillation, France, Sales Forecasts ($m), 2010-2022
  • Figure 14: Multaq, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2010-2022
  • Figure 15: Multaq, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2010-2022
  • Figure 16: Multaq, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2010-2022
  • Figure 17: Distribution of Multaq Sales in % by Countries, 2018
  • Figure 18: Patients Approved for the Drug
Back to Top